Statins are a family of drugs that are used for treating hyperlipidaemia with a recognized
capacity to prevent cardiovascular disease events. They inhibit β‐hydroxy β‐methylglutaryl …

Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase
(HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of …

Observational epidemiological studies have associated plasma lipid concentrations with risk
for coronary heart disease (CHD), but these studies cannot distinguish cause from mere …

Simvastatin is a lipid‐lowering agent used to treat hypercholesterolemia and to reduce the
risk of heart disease. This study scrutinized the beneficial effects of simvastatin on …

Introduction Establishing efficacy of and molecular pathways for statins has the potential to
impact incidence of Alzheimer's and age‐related neurodegenerative diseases (NDD) …

An increasing number of therapeutic agents have been associated with a vasculitic
syndrome. This usually involves small vessels, primarily capillaries, venules, and arterioles …

Objective. The drug efficacy may differ among different statins, and evidence from head‐to‐
head comparisons is sparse and inconsistent. The study is aimed at comparing the lipid …

Statins are an established class of drugs with proven efficacy in cardiovascular risk
reduction. The concern over statin safety was first raised with the revelation of myopathy and …

Objective The statin family of cholesterol-lowering drugs has been shown to induce tumor-
specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway …

Background—The National Heart, Lung, and Blood Institute's Candidate Gene Association
Resource (CARe), a planned cross-cohort analysis of genetic variation in cardiovascular …